Syngene International, a global CRDMO, is adding a GMP bioconjugation suite at its commercial biologics facility [Unit 3] in Bengaluru. With this new capability, Syngene will offer fully integrated, end-to-end services for antibody-drug conjugates (ADCs) – from discovery through to GMP manufacturing. Expected to be operational within this financial year, the conjugation facility will also support a range of advanced conjugates and related modalities. These services are further strengthened by...